Supplementary Table 1. Clinical characteristics of patients who had received platinum-based chemotherapy, n(%)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | CBDCA (n=142,314) | | CDDP (n =86,316) | | p |
|  |  |
| Age (years) | 20-59 | 19,355 | (13.6) | 22,793 | (26.4) | <0.001 |
|  | 60-69 | 52,909 | (37.2) | 43,422 | (50.3) |  |
|  | ≥70 | 70,050 | (49.2) | 20,101 | (23.3) |  |
| Sex | Female | 35,335 | (24.8) | 20,842 | (24.1) | <0.001 |
| Body mass index (kg/m2) | 18.5-22.9 | 66,490 | (46.7) | 41,884 | (48.5) | <0.001 |
|  | -18.4 | 20,108 | (14.1) | 10,245 | (11.9) |  |
|  | 23-25.9 | 36,610 | (25.7) | 23,148 | (26.8) |  |
|  | ≥26 | 17,219 | (12.1) | 10,182 | (11.8) |  |
|  | Missing | 1,887 | (1.3) | 857 | (1.0) |  |
| Smoking (pack-year) | 0 | 37,617 | (26.4) | 22,066 | (25.6) | <0.001 |
|  | 0.1-29.9 | 18,283 | (12.8) | 12,562 | (14.6) |  |
|  | ≥30 | 73,885 | (51.9) | 44,841 | (51.9) |  |
|  | Missing | 12,529 | (8.8) | 6,847 | (7.9) |  |
| Barthel Index | <100 | 16,279 | (11.4) | 4,424 | (5.1) | <0.001 |
|  | 100 | 123,381 | (86.7) | 80,447 | (93.2) |  |
|  | Missing | 2,654 | (1.9) | 1,445 | (1.7) |  |
| Radiotherapy |  | 15,121 | (10.6) | 10,954 | (12.7) | <0.001 |
| Central vein catheter |  | 3,641 | (2.6) | 2,590 | (3.0) | <0.001 |
| Thoracic drainage |  | 3,317 | (2.3) | 1,175 | (1.4) | <0.001 |
| Thoracentesis |  | 3,496 | (2.5) | 1,128 | (1.3) | <0.001 |
| Hypertension |  | 33,093 | (23.3) | 17,757 | (20.6) | <0.001 |
| Diabetes |  | 23,541 | (16.5) | 11,792 | (13.7) | <0.001 |
| Hyperlipidemia |  | 11,617 | (8.2) | 6,170 | (7.1) | <0.001 |
| Atrial fibrillation |  | 3,577 | (2.5) | 1,197 | (1.4) | <0.001 |
| Valvular disorder |  | 374 | (0.3) | 123 | (0.1) | <0.001 |
| Varix |  | 35 | (0.0) | 29 | (0.0) | 0.245 |
| Antithrombotic medication | | 3,223 | (2.3) | 1,116 | (1.3) | <0.001 |

CBDCA, carboplatin; CDDP, cisplatin

Supplementary Table 2. Outcomes of patients who had received platinum-based chemotherapy

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | CBDCA  (n=142,314) | | CDDP (n =86,316) | | p |
|  |
| Venous thromboembolic events, n (%) | 371 | (0.26) | 298 | (0.35) | <0.001 |
| Deep venous thrombosis | 227 | (0.16) | 204 | (0.24) | <0.001 |
| Pulmonary embolism | 116 | (0.08) | 70 | (0.08) | 0.998 |
| Others | 51 | (0.04) | 43 | (0.05) | 0.111 |
| Length of hospital stay, median (IQR) | 17 | (9-25) | 12 | (8-22) | <0.001 |
| Inhospital death, n (%) | 4,227 | (3.0) | 1,031 | (1.2) | <0.001 |

CBDCA, carboplatin; CDDP, cisplatin; IQR, interquartile range

Supplementary Table 3. Multivariable logistic regression analysis for venous thromboembolic events

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | Adjusted odds ratio | 95% confidence interval | | | p |
| Platinum | CBDCA | Reference |  |  |  |  |
|  | CDDP | 1.50 | 1.16 | - | 1.94 | 0.002 |
| Age (years) | 20-59 | Reference |  |  |  |  |
|  | 60-69 | 0.88 | 0.68 | - | 1.14 | 0.333 |
|  | ≥70 | 0.75 | 0.56 | - | 1.00 | 0.049 |
| Sex | Female | 1.17 | 0.90 | - | 1.53 | 0.241 |
| Body mass index (kg/m2) | 18.5-22.9 | Reference |  |  |  |  |
|  | <18.5 | 1.03 | 0.73 | - | 1.43 | 0.883 |
|  | 23-25.9 | 0.97 | 0.74 | - | 1.27 | 0.805 |
|  | ≥26 | 1.21 | 0.87 | - | 1.68 | 0.250 |
|  | Missing | 0.86 | 0.35 | - | 2.08 | 0.733 |
| Smoking (pack-year) | 0 | Reference |  |  |  |  |
|  | 0.1-29.9 | 0.99 | 0.73 | - | 1.35 | 0.973 |
|  | ≥30 | 0.69 | 0.53 | - | 0.90 | 0.006 |
|  | Missing | 0.95 | 0.66 | - | 1.37 | 0.788 |
| Barthel Index | 100 | Reference |  |  |  |  |
|  | <100 | 1.68 | 1.28 | - | 2.22 | <0.001 |
|  | Missing | 1.17 | 0.61 | - | 2.26 | 0.636 |
| Radiotherapy |  | 2.15 | 1.69 | - | 2.73 | <0.001 |
| Central vein catheter |  | 1.66 | 1.05 | - | 2.60 | 0.029 |
| Thoracic drainage |  | 2.52 | 1.67 | - | 3.81 | <0.001 |
| Hypertension |  | 1.11 | 0.88 | - | 1.41 | 0.379 |
| Diabetes |  | 0.72 | 0.52 | - | 1.00 | 0.048 |
| Hyperlipidemia |  | 1.31 | 0.87 | - | 1.98 | 0.197 |
| Atrial fibrillation |  | 0.99 | 0.53 | - | 1.84 | 0.971 |
| Antithrombotic medication |  | 4.65 | 2.95 | - | 7.34 | <0.001 |

CBDCA, carboplatin; CDDP, cisplatin